Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125
Initial clinical sites activated and patient screening underway
Potential for AXA1125 to serve as a first-line therapy for patients with nonalcoholic steatohepatitis (NASH)
CAMBRIDGE, Mass. (BUSINESS WIRE) Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it has activated initial clinical sites and begun patient screening for its EMMPACT Phase 2b clinical trial of AXA1125, the company’s multi-targeted oral product candidate for the treatment of NASH.
“NASH is the quintessential complex disease, involving the dysregulation of numerous biological pathways and impacting an enormous, heterogenous global population,” said Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research in San Antonio, TX, visi
United-states
Cambridge
Cambridgeshire
United-kingdom
San-antonio
Texas
Alison-schecter
Stephena-harrison
Pinnacle-clinical-research
University-of-oxford
Drug-administration
Global-liver-institute